Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Coherus BioSciences (CHRS) Files $100M Common SHelf
March 23, 2015 4:32 PM EDTCoherus BioSciences (NASDAQ: CHRS) filed to sell up to $100 million of its common stock.
... MoreCoherus BioSciences (CHRS) Narrows Q4 Loss
March 23, 2015 4:31 PM EDTCoherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.47), versus ($3.68) reported last year. Revenue for the quarter came in at $6.5 million, versus $1.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
... More